Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Jul 19 03:34PM ET
0.0550
Dollar change
+0.0009
Percentage change
1.66
%
Index- P/E- EPS (ttm)-12.57 Insider Own2.91% Shs Outstand4.70M Perf Week-31.68%
Market Cap0.26M Forward P/E- EPS next Y-2.25 Insider Trans0.00% Shs Float4.58M Perf Month-95.26%
Income- PEG- EPS next Q-2.02 Inst Own23.45% Short Float2.00% Perf Quarter-96.91%
Sales- P/S- EPS this Y62.30% Inst Trans- Short Ratio0.15 Perf Half Y-99.48%
Book/sh0.21 P/B0.26 EPS next Y63.50% ROA- Short Interest0.09M Perf Year-99.72%
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range0.03 - 20.50 Perf YTD-99.53%
Dividend Est.- P/FCF- EPS past 5Y- ROI- 52W High-99.73% Beta0.58
Dividend TTM- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low71.87% ATR (14)0.09
Dividend Ex-Date- Current Ratio- EPS Y/Y TTM38.17% Oper. Margin- RSI (14)16.64 Volatility45.68% 52.12%
Employees14 Debt/Eq- Sales Y/Y TTM-100.00% Profit Margin- Recom1.00 Target Price10.00
Option/ShortNo / Yes LT Debt/Eq- EPS Q/Q- Payout- Rel Volume0.03 Prev Close0.05
Sales Surprise- EPS Surprise0.23% Sales Q/Q- EarningsMay 09 AMC Avg Volume631.17K Price0.05
SMA20-77.68% SMA50-95.00% SMA200-99.36% Trades Volume17,291 Change1.66%
Date Action Analyst Rating Change Price Target Change
Jan-25-22Downgrade Stifel Buy → Hold $20 → $6.20
Nov-09-21Upgrade Stifel Hold → Buy $20
Oct-12-21Initiated Credit Suisse Outperform $20
Oct-04-21Initiated Mizuho Buy $20
Sep-21-21Initiated JMP Securities Mkt Outperform $33
Sep-20-21Initiated Stifel Hold $20
Sep-13-21Initiated Cantor Fitzgerald Overweight $50
Jun-26-24 07:41AM
Jun-24-24 10:19AM
07:00AM
May-20-24 08:30AM
May-09-24 10:56PM
04:01PM Loading…
04:01PM
Apr-09-24 08:00AM
Apr-05-24 12:58PM
Apr-04-24 08:30AM
Mar-25-24 09:53PM
04:01PM
Feb-05-24 08:30AM
Jan-30-24 09:55AM
Jan-29-24 04:05PM
Jan-25-24 08:00AM
08:05AM Loading…
Jan-09-24 08:05AM
08:00AM
Dec-08-23 08:15AM
Nov-28-23 08:00AM
Nov-15-23 08:00AM
Nov-13-23 04:14PM
Nov-06-23 08:00AM
Oct-24-23 08:00AM
Sep-11-23 08:00AM
Aug-30-23 08:00AM
Aug-11-23 06:05AM
Aug-08-23 04:01PM
Jun-08-23 04:01PM
Jun-07-23 08:00AM
May-31-23 05:43PM
09:00AM Loading…
May-26-23 09:00AM
May-25-23 04:50PM
May-09-23 04:01PM
May-08-23 08:00AM
Apr-26-23 04:01PM
Apr-11-23 08:00AM
Mar-28-23 08:30AM
Mar-08-23 04:01PM
Feb-21-23 08:30AM
Jan-30-23 08:00AM
Jan-05-23 04:01PM
Nov-07-22 04:00PM
Oct-31-22 02:05PM
Oct-26-22 08:00AM
Sep-26-22 08:00AM
Sep-21-22 09:00AM
Sep-14-22 08:00AM
Sep-06-22 08:30AM
Aug-09-22 04:01PM
Aug-08-22 05:30AM
Jun-07-22 08:00AM
Jun-05-22 05:00PM
May-26-22 05:15PM
May-10-22 04:02PM
May-03-22 06:45AM
May-02-22 04:04PM
Apr-04-22 08:30AM
Mar-16-22 04:01PM
Feb-16-22 08:30AM
Feb-15-22 06:53PM
Feb-09-22 04:00PM
Jan-24-22 04:00PM
Nov-24-21 08:00AM
Nov-22-21 08:00AM
Nov-08-21 07:00AM
Nov-04-21 09:08AM
Nov-01-21 04:05PM
Oct-26-21 08:00AM
Oct-07-21 04:30PM
Sep-30-21 04:32PM
Sep-16-21 08:00AM
eFFECTOR Therapeutics, Inc., a biopharmaceutical company, engages in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer. The company's lead product candidates comprise Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer; and Zotatifin, a small molecule inhibitor of eukaryotic initiation factor 4A (eIF4E), which is in Phase 1/2 clinical trial to treat patients with solid tumors, as well as completed Phase 2a open-label expansion cohort in combination with fulvestrant and abemaciclib to treat patients with ER+ breast cancer. The company has a research collaboration and license agreement with Pfizer Inc. to research and develop small molecules that target eIF4E; and collaboration agreement with the Dana-Farber Cancer Institute on a Phase 2 clinical trial, evaluating Zotatifin as combination treatment in ER+ endometrial cancer and in low grade serous ovarian cancer. eFFECTOR Therapeutics, Inc. was incorporated in 2012 and is headquartered in Solana Beach, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
SR ONE CAPITAL MANAGEMENT, LLC10% OwnerNov 27 '23Sale0.61609,163369,4571,821,415Nov 29 05:07 PM
WORLAND STEPHEN TChief Executive OfficerAug 11 '23Option Exercise0.5233,79917,575261,225Aug 14 08:00 AM